Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality
Biological Procedures Online volume 8, pages 55–62 (2006)
The application of naked DNA containing type I interferon (IFN) transgenes is a promising potential therapeutic approach for controlling chronic viral infections. Herein, we detail the application of this approach that has been extensively used to restrain ocular HSV-1 infection, for antagonizing vaginal HSV-2 infection. We show that application of IFN-α1, -α 5, and -β transgenes to vaginal mouse lumen 24 hours prior to HSV-2 infection reduces HSV-2 mediated mortality by 2.5 to 3-fold. However, other type I IFN transgenes (IFN- α 4, -α 5, -α 6, and -α 9) are non effectual against HSV-2. We further show that the efficacy of IFN-1 transgene treatment is independent of CD4+ T lymphocytes. However, in mice depleted of CD8+ T lymphocytes, the ability of IFN-α 1 transgene treatment to antagonize HSV-2 was lost.
Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337(16):1105–1111.
Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, et al. HSV-2 transmission. Antiviral Res 2004; 63 Suppl 1:S27-S35.
Cherpes TL, Melan MA, Kant JA, Cosentino LA, Meyn LA, Hillier SL. Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis 2005; 40(10):1422–1428.
Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, Ndinya-Achola J, et al. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis 2000; 181(1):58–63.
Wald A. Herpes simplex virus type 2 transmission: risk factors and virus shedding. Herpes 2004; 11 Suppl 3:130A-137A.
Celum C, Levine R, Weaver M, Wald A. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 2004; 82(6):447–453.
Wolff MH, Schmitt J, Rahaus M, Dudda H, Hatzmann W. Clinical and subclinical reactivation of genital herpes virus. Intervirology 2002; 45(1):20–23.
Raguin G, Malkin JE. Genital herpes: epidemiology and pathophysiology. Update and new perspectives. Ann Med Interne (Paris) 1997; 148(8):530–533.
Liu V, Bigby M. Reactivation of genital herpes simplex virus 2 infection in asymptomatic seropositive persons is frequent. Arch Dermatol 2000; 136(9):1141–1142.
Tran TH, Stanescu D, Caspers-Velu L, Rozenberg F, Liesnard C, Gaudric A, et al. Clinical characteristics of acute HSV-2 retinal necrosis. Am J Ophthalmol 2004; 137(5):872–879.
Inoda S, Wakakura M, Hirata J, Nakazato N, Toyo-Oka Y. Stromal keratitis and anterior uveitis due to herpes simplex virus-2 in a young child. Jpn J Ophthalmol 2001; 45(6):618–621.
Kleinschmidt-DeMasters BK, Gilden DH. The expanding spectrum of herpesvirus infections of the nervous system. Brain Pathol 2001; 11(4):440–451.
Corey L. The current trend in genital herpes. Progress in prevention. Sex Transm Dis 1994; 21(2 Suppl):S38-S44.
Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Jama 1999; 282(4):331–340.
Rajcani J, Mosko T, Rezuchova I. Current developments in viral DNA vaccines: shall they solve the unsolved? Rev Med Virol 2005; 15(5):303–325.
Rouse BT, Nair S, Rouse RJ, Yu Z, Kuklin N, Karem K, et al. DNA vaccines and immunity to herpes simplex virus. Curr Top Microbiol Immunol 1998; 226:69–78.
Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000; 30(3):549–566.
McClements WL, Armstrong ME, Keys RD, Liu MA. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine 1997; 15(8):857–860.
Lee HH, Cha SC, Jang DJ, Lee JK, Choo DW, Kim YS, et al. Immunization with combined HSV-2 glycoproteins B2: D2 gene DNAs: protection against lethal intravaginal challenges in mice. Virus Genes 2002; 25(2):179–188.
Nass PH, Elkins KL, Weir JP. Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection. Vaccine 2001; 19(11–12):1538–1546.
Lee S, Gierynska M, Eo SK, Kuklin N, Rouse BT. Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes Infect 2003; 5(7):571–578.
Emonyi IW, Gray RH, Zenilman J, Schmidt K, Wawer MJ, Sewankambo KN, et al. Sero-prevalence of Herpes simplex virus type 2 (HSV-2) in Rakai district, Uganda. East Afr Med J 2000; 77(8):428–430.
Austin BA, James C, Silverman RH, Carr DJ. Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute ocular herpes simplex virus type 1 infection. J Immunol 2005; 175(2):1100–1106.
Harle P, Noisakran S, Carr DJ. The application of a plasmid DNA encoding IFN-alpha 1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice. J Immunol 2001; 166(3):1803–1812.
Carr DJ, Tomanek L, Silverman RH, Campbell IL, Williams BR. RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2. J Virol 2005; 79(14):9341–9345.
Baker DA, Plotkin SA. Enhancement of vaginal infection in mice by herpes simmplex virus type II with progesterone. Proc Soc Exp Biol Med 1978; 158:131–134.
Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, Parr EL. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 1994; 70(3):369–380.
Harland J, Brown SM. HSV growth, preparation, and assay. Totowa, NJ: Humana Press; 1998.
Noisakran S, Carr DJ. Plasmid DNA encoding IFNalpha 1 antagonizes herpes simplex virus type 1 ocular infection through CD4+ and CD8+ T lymphocytes. J Immunol 2000; 164(12):6435–6443.
Harle P, Cull V, Guo L, Papin J, Lawson C, Carr DJ. Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection. Antiviral Res 2002; 56(1):39–49.
Kelley KA, Pitha PM. Characterization of a mouse interferon gene locus I. Isolation of a cluster of four alpha interferon genes. Nucleic Acids Res 1985; 13(3):805–823.
Seif I, De Maeyer-Guignard J. Structure and expression of a new murine interferon-alpha gene: MuIFN-alpha I9. Gene 1986; 43(1–2):111–121.
Lawson CM, Yeow WS, Lee CM, Beilharz MW. In vivo expression of an interferon-alpha gene by intramuscular injection of naked DNA. J Interferon Cytokine Res 1997; 17(5):255–261.
Yeow WS, Lawson CM, Beilharz MW. Antiviral activities of individual murine IFN-alpha subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. J Immunol 1998; 160(6):2932–2939.
Halford WP, Veress LA, Gebhardt BM, Carr DJ. Innate and acquired immunity to herpes simplex virus type 1. Virology 1997; 236(2):328–337.
Harle P, Lauret E, Pitha PM, De Maeyer E, Carr DJ. Expression of human and macaque type I IFN transgenes interferes with HSV-1 replication at the transcriptional and translational levels: IFN-beta is more potent than IFN-alpha 2. Virology 2001; 290(2):237–248.
Noisakran S, Campbell IL, Carr DJ. Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. J Immunol 1999; 162(7):4184–4190.
Noisakran SJ, Carr DJ. Therapeutic efficacy of DNA encoding IFN-alpha1 against corneal HSV-1 infection. Curr Eye Res 2000; 20(5):405–412.
Noisakran S, Carr DJ. Type I interferons and herpes simplex virus infection: a naked DNA approach as a therapeutic option? Immunol Res 2001; 24(1):1–11.
Noisakran S, Carr DJ. Topical application of the cornea post-infection with plasmid DNA encoding interferon-alpha1 but not recombinant interferonalphaA reduces herpes simplex virus type 1-induced mortality in mice. J Neuroimmunol 2001; 121(1–2):49–58.
Harle P, Cull V, Agbaga MP, Silverman R, Williams BR, James C, et al. Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication. J Virol 2002; 76(13):6558–6567.
Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175(2):633–639.
Bartlett EJ, Cull VS, Mowe EN, Mansfield JP, James CM. Optimization of Naked DNA Delivery for Interferon Subtype Immunotherapy in Cytomegalovirus Infection. Biol Proced Online 2003; 5:43–52.
Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282(5388):476–480.
Tuting T, Austyn J, Storkus WJ, Falo LD Jr. The Immunology of DNA Vaccines. In: Lowrie DB, and Whalen, R. G., editor. DNA Vaccines: Methods and Protocols. Totawa, NJ: Humana Press Inc.; 2000. p. 37–64.
Mumper RJ, Ledebur HC Jr., Rolland AP, Tomlinson E. Controlled Plasmid Delivery and Gene Expression. In: Lowrie DB, and Whalen, R. G., editor. DNA Vaccines: Methods and Protocols. Totawa, NJ: Humana Press Inc.; 2000. p. 267–286.
Tan PH, Manunta M, Ardjomand N, Xue SA, Larkin DF, Haskard DO, et al. Antibody targeted gene transfer to endothelium. J Gene Med 2003; 5(4):311–323.
Liang KW, Hoffman EP, Huang L. Targeted delivery of plasmid DNA to myogenic cells via transferrinconjugated peptide nucleic acid. Mol Ther 2000; 1(3):236–243.
Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
About this article
Cite this article
Austin, B.A., James, C.M., Härle, P. et al. Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality. Biol. Proced. Online 8, 55–62 (2006). https://doi.org/10.1251/bpo118